Literature DB >> 24171557

Pre-exposing Canada Geese (Branta canadensis) to a low-pathogenic H1N1 avian influenza virus protects them against H5N1 HPAI virus challenge.

Yohannes Berhane1, Carissa Embury-Hyatt, Marsha Leith, Helen Kehler, Matthew Suderman, John Pasick.   

Abstract

In previous studies we examined the role of Canada Geese (Branta canadensis) in the epidemiology of Eurasian highly pathogenic avian influenza (HPAI) H5N1. To expand on this and better understand how pre-exposure to heterosubtypic low-pathogenic avian influenza (LPAI) viruses might influence the outcome of H5N1 HPAI infection, we pre-exposed naïve juvenile Canada Geese to different North American wild-bird-origin LPAI viruses. We selected H1, H2, and H6 hemagglutinin subtype viruses based on their higher-order evolutionary relatedness to the H5 hemagglutinin. Pre-exposing Canada Geese to either H2N3 or H6N5 viruses did not protect them against a lethal H5N1 HPAI virus challenge. In addition, H5N1 was transmitted to naïve control birds that were placed among both groups resulting in death by 5 days postcontact. In contrast, Canada Geese that were pre-exposed to H1N1 were protected against a lethal H5N1 challenge, shed minimal amounts of the virus into the environment, and did not transmit the infection to naïve contact birds. None of the H1N1, H2N3, or H6N5 pre-exposure sera neutralized H5N1 in vitro; however, sera from H1N1-infected birds reduced virus plaque size but not number when compared with H2N3, H6N5, or negative sera, suggesting that antibodies directed against the neuraminidase may have had a role in the protective effects observed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24171557     DOI: 10.7589/2012-09-237

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  6 in total

1.  Subtype-specific influenza A virus antibodies in Canada geese (Branta canadensis).

Authors:  Whitney M Kistler; David E Stallknecht; Thomas J DeLiberto; Kyle Van Why; Michael J Yabsley
Journal:  Vet Microbiol       Date:  2015-03-30       Impact factor: 3.293

2.  Naturally Acquired Antibodies to Influenza A Virus in Fall-Migrating North American Mallards.

Authors:  David E Stallknecht; Alinde Fojtik; Deborah L Carter; Jo Anne Crum-Bradley; Daniel R Perez; Rebecca L Poulson
Journal:  Vet Sci       Date:  2022-04-27

3.  LIMITED DETECTION OF ANTIBODIES TO CLADE 2.3.4.4 A/GOOSE/GUANGDONG/1/1996 LINEAGE HIGHLY PATHOGENIC H5 AVIAN INFLUENZA VIRUS IN NORTH AMERICAN WATERFOWL.

Authors:  David E Stallknecht; Clara Kienzle-Dean; Nick Davis-Fields; Christopher S Jennelle; Andrew S Bowman; Jacqueline M Nolting; Walter M Boyce; James M Crum; Jefferson J S Santos; Justin D Brown; Diann J Prosser; Susan E W De La Cruz; Joshua T Ackerman; Michael L Casazza; Scott Krauss; Daniel R Perez; Andrew M Ramey; Rebecca L Poulson
Journal:  J Wildl Dis       Date:  2019-09-26       Impact factor: 1.535

4.  Serological evidence for non-lethal exposures of Mongolian wild birds to highly pathogenic avian influenza H5N1 virus.

Authors:  Martin Gilbert; Björn F Koel; Theo M Bestebroer; Nicola S Lewis; Derek J Smith; Ron A M Fouchier
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

5.  Infectivity, transmission and pathogenicity of H5 highly pathogenic avian influenza clade 2.3.4.4 (H5N8 and H5N2) United States index viruses in Pekin ducks and Chinese geese.

Authors:  Mary J Pantin-Jackwood; Mar Costa-Hurtado; Kateri Bertran; Eric DeJesus; Diane Smith; David E Swayne
Journal:  Vet Res       Date:  2017-06-07       Impact factor: 3.683

6.  Comparative micro-epidemiology of pathogenic avian influenza virus outbreaks in a wild bird population.

Authors:  Sarah C Hill; Rowena Hansen; Samantha Watson; Vivien Coward; Christine Russell; Jayne Cooper; Steve Essen; Holly Everest; Kris V Parag; Steven Fiddaman; Scott Reid; Nicola Lewis; Sharon M Brookes; Adrian L Smith; Ben Sheldon; Christopher M Perrins; Ian H Brown; Oliver G Pybus
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-06-24       Impact factor: 6.237

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.